Skip to content

塞塔拉

US · CERT #2994 按市值排名 上市于 2020
9.37 -0.29 -3.00%
实时 - 追踪5344个代码 - 心跳于449秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 1.46 低于历史水平 第18百分位
5年平均 2.36 · 在Health Information Services中排名第16/41
市盈率 -21.07 高于历史水平 第71百分位
5年平均 -92.02 · 前瞻 -301.84
市销率 3.35 低于历史水平 第15百分位
5年平均 7.31 · 前瞻 3.73 · 在Health Information Services中排名第26/42

同业对比 Health Information Services

公司 市值 市盈率(TTM) 市净率 股息率
塞塔拉 (CERT) 1.43B -21.30 1.48 0.00%
Veeva Systems (VEEV) 50.25B 50.88 6.76 0.00%
BrightSpring Health Services (BTSG) 12.04B 36.89 5.88 0.00%
Tempus AI (TEM) 11.68B -44.94 26.24 0.00%
Hinge Health (HNGE) 8.00B 74.11 23.24 0.00%
HealthEquity (HQY) 7.61B 33.22 3.83 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值12.97 经济护城河None 不确定性High

当前股价低于晨星合理价值估算38.4%。

合理价值

On the surface, Certara Inc appears cheap due to significant downward price pressure over the past year. To incorporate the risk associated with a potential value trap, we have capped its rating at 3 stars. The stock currently trades at a 29% discount to our quantitative fair value estimate of $12.97 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 67.7%, which sits in the top 45% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

Alternatively, the firm's lack of growth is potentially concerning. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's EBIT 3-year growth, for example, sits in the bottom 1% globally. Earnings before interest and taxes has exhibited poor growth over the last three years. The future could be difficult for the firm, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:20 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

塞塔拉 讨论区 0 条评论

发表评论